Some people experience significant blood sugar improvement and weight loss, while others may see more modest benefits or struggle with side effects
The retail pharmacies segment contributed the biggest market share of 54% in 2025, driven by the primary dispensing channel for chronic therapy
Rising Awareness and Access Issues Are Shaping Demand 47% of GLP-1 users are aware of the FDA's new policy shift that has restricted the availability of compounded semaglutide on the market, and 17% say it's been harder to get their medication because of it
These prices represent a dramatic shift from the $1,000+ list prices that defined GLP-1 medications just two years ago
The stage was set for Habener, Drucker, Svetlana Mosjov, Lise Heding, Jens Holst, Michael Nauck, and many others, to elucidate the function of GLP-1 in cells, lab animals, and humans